Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10217147 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Kops GJ, et al. (1999) Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398, 630-4 10217147
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S197-p - FOXO4 (human) ▲
Orthologous residues
FOXO4 (human): S197‑p, FOXO4 (mouse): S197‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phosphoamino acid analysis, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], Rat1 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) genetic transfer of dominant-negative enzyme, inhibition of upstream enzyme, transfection of constitutively active enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
PDGF increase
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (process):  transcription, altered

S262-p - FOXO4 (human) ▲
Orthologous residues
FOXO4 (human): S262‑p, FOXO4 (mouse): S262‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phosphoamino acid analysis, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], Rat1 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) genetic transfer of dominant-negative enzyme, inhibition of upstream enzyme, transfection of constitutively active enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
PDGF increase
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (process):  transcription, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.